Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease.: 2.: Potency and chirality

被引:61
作者
Borthwick, AD
Crame, AJ
Ertl, PF
Exall, AM
Haley, TM
Hart, GJ
Mason, AM
Pennell, AMK
Singh, OMP
Weingarten, GG
Woolven, JM
机构
[1] Glaxo Wellcome Res & Dev Ltd, Dept Med Chem, CVU UK, Med Res Ctr,Dept Mol Immunol, Stevenage SG1 2NY, Herts, England
[2] Glaxo Wellcome Res & Dev Ltd, Dept Med Chem, CVU UK, Med Res Ctr,Dept Biomol Struct, Stevenage SG1 2NY, Herts, England
[3] Glaxo Wellcome Res & Dev Ltd, Dept Med Chem, CVU UK, Med Res Ctr,Dept Enzyme Pharmacol, Stevenage SG1 2NY, Herts, England
关键词
D O I
10.1021/jm0102203
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The stereospecific synthesis of a series of alpha-methylpyrrolidine-5,5-trans-lactam inhibitors of human cytomegalovirus (HCMV) protease is described. Examination of the SAR in this series has defined the size and chirality of the alpha-substituent, optimized the acyl substituent on the lactam nitrogen, and defined the steric constraint of this functionality. The SAR of the functionality on the pyrrolidine nitrogen of the trans-lactam has been investigated, and this has led to the discovery of potent serine protease inhibitors that are highly selective for the viral enzyme over the mammalian enzymes elastase, thrombin, and acetylcholine esterase. The mechanism of action of our lead compounds has been established by mass spectrometry, and enzymatic degradation of HCMV deltaAla protease acylated with these inhibitors showed that Ser 132 is the active site nucleophile. The crystal structure of HCMV protease was obtained and used to model the conformationally restricted, chiral (S)-proline-alpha-methyl-5,5-trans-lactams into the active site groove of the enzyme, enabling us to direct and rationalize the SAR in this series. The activity against HCMV deltaAla protease is the greatest with inhibitors based on the dansyl-(S)-proline alpha-methyl-5,5-trans-lactam template, which have low nanomolar activity against the viral enzyme.
引用
收藏
页码:1 / 18
页数:18
相关论文
共 20 条
[1]   THE REACTION OF 3-CHLOROSULFONYLBENZOYL CHLORIDE WITH AMINES [J].
BARR, CR ;
SALMINEN, IF ;
WEISSBERGER, A .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1951, 73 (09) :4131-4133
[2]   ACTIVATION AND COUPLING OF PYRROLE-1-CARBOXYLIC ACID IN THE FORMATION OF PYRROLE N-CARBONYL COMPOUNDS - PYRROLE-1-CARBOXYLIC ACID ANHYDRIDE [J].
BOGER, DL ;
PATEL, M .
JOURNAL OF ORGANIC CHEMISTRY, 1987, 52 (11) :2319-2323
[3]   Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxo-hexahydro-pyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease.: 1.: The α-methyl-trans-lactam template [J].
Borthwick, AD ;
Angier, SJ ;
Crame, AJ ;
Exall, AM ;
Haley, TM ;
Hart, GJ ;
Mason, AM ;
Pennell, AMK ;
Weingarten, GG .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (23) :4452-4464
[4]   Stereoselective synthesis of gem-dimethyl-5,5-pyrrolidine-trans-lactam (5-oxo-hexahydropyrrolo[3,2-b]pyrrole) [J].
Borthwick, AD ;
Davies, DE ;
Exall, AM ;
Pennell, AMK ;
Richards, JJ .
TETRAHEDRON LETTERS, 2001, 42 (39) :6933-6935
[5]  
Borthwick AD, 2000, SYNLETT, P504
[6]   Design and synthesis of monocyclic β-lactams as mechanism-based inhibitors of human cytomegalovirus protease. [J].
Borthwick, AD ;
Weingarten, G ;
Haley, TM ;
Tomaszewski, M ;
Wang, W ;
Hu, ZH ;
Bedard, J ;
Jin, HL ;
Yuen, L ;
Mansour, TS .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (04) :365-370
[7]  
BOX DS, 2000, J MED CHEM, V43, P4452
[8]   Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad [J].
Chen, P ;
Tsuge, H ;
Almassy, RJ ;
Gribskov, CL ;
Katoh, S ;
Vanderpool, DL ;
Margosiak, SA ;
Pinko, C ;
Matthews, DA ;
Kan, CC .
CELL, 1996, 86 (05) :835-843
[9]   HUMAN CYTOMEGALOVIRUS PROTEINASE - CANDIDATE GLUTAMIC-ACID IDENTIFIED AS 3RD MEMBER OF PUTATIVE ACTIVE-SITE TRIAD [J].
COX, GA ;
WAKULCHIK, M ;
SASSMANNSHAUSEN, LM ;
GIBSON, W ;
VILLARREAL, EC .
JOURNAL OF VIROLOGY, 1995, 69 (07) :4524-4528
[10]  
Gibson W., 1995, PERSPECT DRUG DISCOV, V2, P413